News | Population Health | October 18, 2019

New Registry to Provide Insight into STEMI Occurrence, Treatment in North India

First prospective cohort study of this magnitude in the region already providing unique data about opportunities to improve STEMI management in India

New Registry to Provide Insight into STEMI Occurrence, Treatment in North India

Image courtesy of UNC School of Medicine


October 18, 2019 — A new study published in Clinical Cardiology[1] introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction (STEMI) Registry and provides preliminary data collected since its start in January of this year. The prospective cohort study’s first author, Sameer Arora, M.D., UNC School of Medicine cardiology fellow and preventive medicine resident, says researchers will follow approximately 3,500 patients admitted for STEMI treatment to two government-funded medical centers in New Delhi, India.

These hospitals serve a large proportion of the patients with lower socioeconomic status presenting from multiple states in India, as many centers in these states lack adequate specialized cardiovascular care. The NORIN STEMI registry aims to provide important insights regarding contemporary risk factors profiles, practice patterns and prognosis in patients with STEMI in an underserved population in North India. These findings may identify opportunities to improve the outcomes of patients with STEMI in the country.

From January through March of this year, 558 patients were registered in the study. Preliminary data from those patients is already providing insight into this population that has not been available previously.

“We have found that only 14 percent of patients being treated for STEMI at these hospitals are women, which is much lower than the average number of women having this kind of heart attack in the United States,” Arora said. “We suspect 14 percent is also lower than the actual average of women having STEMI in North India, but we need to understand why more women aren’t making it to the hospital for treatment.”

Researchers have also found the average age of STEMI patients in this study is nearly ten years younger than the average age of patients in Europe and the U.S. About a third of the patients are less than 50 years old. Arora says this is exactly the kind of information that will provide more insight into population health in that region and help improve treatment for STEMI.

Throughout the course of the study, researchers will follow up with patients several times within one year of their initial treatment for STEMI. The study is currently un-funded.

For more information: www.onlinelibrary.wiley.com

Reference

1. Arora S., Qamar A., Gupta P., et al. Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. Clinical Cardiology, published online Oct. 8, 2019. https://doi.org/10.1002/clc.23278


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now